Theravance Biopharma (TBPH) Short term Debt (2019 - 2022)

Theravance Biopharma (TBPH) has 4 years of Short term Debt data on file, last reported at $9.0 million in Q1 2022.

• Short term Debt for Q1 2022 came in at $9.0 million, down 22.7% year-over-year; the trailing twelve-month figure through Mar 2022 was $9.0 million (down 22.7% YoY), and the FY2021 annual result was $16.9 million, down 12.38% from the prior year.
• Short term Debt retreated to $9.0 million in Q1 2022 per TBPH's latest filing, from $16.9 million in the prior quarter.
• Over five years, Short term Debt peaked at $19.3 million in Q4 2020 and troughed at $6.9 million in Q2 2021.
• A 4-year average of $11.6 million and a median of $10.8 million in 2019 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2020 and 2022: Short term Debt surged 96.26% in 2020, then declined 22.7% in 2022.
• A 4-year view of Short term Debt shows it stood at $9.9 million in 2019, then surged by 96.26% to $19.3 million in 2020, then retreated by 12.38% to $16.9 million in 2021, then slumped by 46.8% to $9.0 million in 2022.
• Business Quant data shows TBPH's Short term Debt at $9.0 million in Q1 2022, $16.9 million in Q4 2021, and $12.5 million in Q3 2021.